William Blair Issues Optimistic Outlook for Medpace Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) – Stock analysts at William Blair lifted their Q4 2024 earnings estimates for Medpace in a research report issued on Tuesday, October 22nd. William Blair analyst M. Smock now forecasts that the company will post earnings of $2.87 per share for the quarter, up from their prior estimate of $2.86. William Blair has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.64 per share. William Blair also issued estimates for Medpace’s Q2 2025 earnings at $3.06 EPS.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a net margin of 16.74% and a return on equity of 55.14%. Medpace’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.22 earnings per share.

Other equities analysts also recently issued research reports about the company. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. TD Cowen lowered their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday. UBS Group cut Medpace from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. Finally, Truist Financial lowered their price objective on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $380.00.

Medpace Price Performance

Shares of MEDP stock opened at $328.08 on Friday. The firm has a market cap of $10.16 billion, a P/E ratio of 33.44, a PEG ratio of 1.77 and a beta of 1.35. Medpace has a fifty-two week low of $239.00 and a fifty-two week high of $459.77. The stock’s 50-day moving average is $352.59 and its two-hundred day moving average is $381.83.

Institutional Investors Weigh In On Medpace

Several hedge funds have recently modified their holdings of MEDP. Westwind Capital boosted its holdings in Medpace by 800.1% in the 2nd quarter. Westwind Capital now owns 380,929 shares of the company’s stock valued at $156,886,000 after purchasing an additional 338,610 shares during the period. Findlay Park Partners LLP acquired a new stake in Medpace during the first quarter worth about $90,247,000. Clearbridge Investments LLC grew its position in Medpace by 302.4% during the first quarter. Clearbridge Investments LLC now owns 260,411 shares of the company’s stock worth $105,245,000 after buying an additional 195,698 shares in the last quarter. Renaissance Technologies LLC increased its stake in Medpace by 38.3% during the second quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock valued at $182,692,000 after acquiring an additional 122,800 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Medpace by 62.3% in the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock valued at $127,941,000 after acquiring an additional 119,257 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.